Our overall aim is to characterise new drug scaffolds and their novel binding sites on HIV reverse transcriptase to advance fundamental understanding of reverse transcriptase structure and function and to underpin the discovery of a new HIV drug class.

This new drug class is aimed to have a distinct mechanism of action and resistance profile to drugs currently used for HIV treatment and prevention

Timeline

2017 – 2019

Publications

2016

• Why Do We Need New Drug Classes for HIV Treatment and Prevention?
  Waheed AA, Tachedjian G
  Curr Top Med Chem. 2016 May; 16(12):1343-1349
• Editorial: Current and Emerging Drug Targets for Human Immunodeficiency Virus.
  Waheed AA, Tachedjian G
  Curr Top Med Chem. 2016 Apr; 16(10):1072-1073
• Fragment Based Strategies for Discovery of Novel HIV-1 Reverse Transcriptase and Integrase Inhibitors.
  Latham CF, La J, Tinetti RN, Chalmers DK, Tachedjian G
  Curr Top Med Chem. 2016 Mar; 16(10):1135-1153

2015

• Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening.
  La J, Latham CF, Tinetti RN, Johnson A, Tyssen D, Huber KD, Sluis-Cremer N, Simpson JS, Headey SJ, Chalmers DK, Tachedjian G
  PNAS. 2015 May; 112(22):6979-6984